<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="1177">
  <stage>Registered</stage>
  <submitdate>23/03/2006</submitdate>
  <approvaldate>23/06/2006</approvaldate>
  <actrnumber>ACTRN12606000253505</actrnumber>
  <trial_identification>
    <studytitle>The treatment of depression in Parkinson's Disease using mifepristone.</studytitle>
    <scientifictitle>A pilot, double-blind crossover trial of the glucocorticoid antagonist mifepristone (RU-486) in the treatment of depression in patients with Parkinson's disease.</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Diagnostic and Statistical Manual 4th edition (DSM-IV) Major Depressive Episode in patients with Parkinson's Disease.</healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Parkinson's disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Depression</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Mifepristone 600mg orally (3x200mg tablets) daily for 7 days.</interventions>
    <comparator>Placebo (3 identical tablets) orally daily for 7 days .</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Montgomery Asberg Depression Rating Scale (MADRS)</outcome>
      <timepoint>At 2 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Hamilton Depression Rating Scale (HDRS) </outcome>
      <timepoint>At 2 weeks.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Global Assessment of Functioning (GAF)</outcome>
      <timepoint>At 2 weeks.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cognitive tests at 2 weeks (Hopkins Verbal Learning Test, Verbal fluency using letters "F""A""S" and equivalents, Digit span forwards and backwards, Benton Judgement of Line Orientation).</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Unified Parkinson's Disease Rating Scale (UPDRS) at completion of course of medication.</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>PD (UK Brain Bank criteria), DSM-IV Major Depressive Episode, Mini-mental state examination (MMSE) score &gt;23.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Depression complicated by active suicidal intent or requiring urgent treatment/hospitilisation, Current use steroid medications, Severe asthma/respiratory disease, Chronic adrenal, renal or hepatic failure, Females of child-bearing potential. Males and females eligible for study.  Females of child-bearing potential are excluded.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>The randomisation code will be held only by the pharmacist and the placebo tablets used will be identical to the mifepristone tablets.  All medication will be dispensed by one hospital pharmacy.  A statistician will generate the randomisation code and give this to the pharmacist but not the investigators.  The investigators will give participants a standard presciption form to take to the pharmacy which will be the same regardless of whether mifepristone or placebo will be dispensed.</concealment>
    <sequence>Intervention order (mifepristone versus placebo) determined by computerised method using Microsoft Excel random number generator and balanced in blocks.  Block sizes not variable.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>27/03/2006</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>20</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Charities/Societies/Foundations</primarysponsortype>
    <primarysponsorname>Neurological Foundation</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Neurological Foundation</fundingname>
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>None</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>A crossover trial of mifepristone for the treatment of depression in Parkinson's disease.  

Participants will be randomly assigned to either mifepristone or placebo during the first part of the study and then assigned to the other during the second part of the study.

The trial will be double blinded - the placebo and mifepristone are to be dispensed by a hospital pharmacy according to a code generated by a statistician.  Participants and investigators will not know which has been dispensed until the completion of the trial.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Upper South B ethics committee -Christchurch</ethicname>
      <ethicaddress />
      <ethicapprovaldate>28/02/2005</ethicapprovaldate>
      <hrec>URB/04/12/011</hrec>
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Colin Peebles</name>
      <address>Princess Margaret Hospital
Cashmere Road
PO Box 800
Christchurch</address>
      <phone>+64 3 3377969</phone>
      <fax />
      <email>colin.peebles@cdhb.govt.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Colin Peebles</name>
      <address>Princess Margaret Hospital
Cashmere Road
PO Box 800
Christchurch</address>
      <phone>+64 3 3377969</phone>
      <fax />
      <email>colin.peebles@cdhb.govt.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>